Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 829-836

  Martin, Lesley Ann ^a   Davies, Giles L S ^b   Weigel, Marion T ^a   Betambeau, Nadine ^b   Hills, Margaret J ^b   Salter, Janine ^b   Walsh, Geraldine ^b   A'Hern, Roger ^b   Dowsett, Mitch ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Celecoxib; COX 2; Estrogen receptor; Ki67; Pre surgical study

Indexed keywords

CD31 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOPSY; BREAST TUMOR; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOPSY; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KI-67 ANTIGEN; LONDON; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTMENOPAUSE; PYRAZOLES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952115573     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1100-z     Document Type: Article

References (48)

1. Mehta RG, Moon RC (1991) Characterization of effective chemo preventive agents in mammary gland in vitro using an initiation-promotion protocol. Anticancer Res 11:593-596
2. Thun MJ, Namboodiri MM, Heath CW Jr. (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596
3. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355-358
4. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618-1619 (Pubitemid 24007679)
5. Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316 (Pubitemid 23131373)
6. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988-993 (Pubitemid 26239387)
7. Harris RE, Namboodiri KK, Farrar WB (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7:203-205 (Pubitemid 26068056)
8. Takkouche B, Regueira-Méndez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: A metaanalysis. J Natl Cancer Inst 100:1439-1447
9. Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: An updated quantitative review to 2005. Cancer Causes Control 17:871-888 (Pubitemid 44081706)
10. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-Analysis. BMC Cancer 3:28
11. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: A meta-Analysis. Br J Cancer 84:1188-1192 (Pubitemid 32511336)
12. Mangiapane S, Blettner M, Schlattmann P (2008) Aspirin use and breast cancer risk: A meta-Analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 17:115-124 (Pubitemid 351308510)
13. Davies G, Martin L-A, Sacks N, Dowsett M (2002) Cyclooxygenase (COX-2), aromatase and breast cancer: A possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13:669-678 (Pubitemid 34567372)
14. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140:27-35 (Pubitemid 29251310)
15. Subbaramaiah K, Norton L, Gerald W et al. (1999) Increased expression of cyclooxygenase-2 in HER-2-overexpressing human breast cancer cells. In: NCI 7th SPORE investigators workshop
16. Bennett A (1986) The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res 25:539-542
17. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M (1980) Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64:1061-1070 (Pubitemid 10100318)
18. Schrey MP, Patel KV (1995) Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72:1412-1419
19. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004) Cyclooxygenase 2(COX2) expression is associated with poor outcome in ER-negative, but not ER-positive breast cancer. Histopathology 45:47-54 (Pubitemid 38969561)
20. Liu CH, Chang SH, Narko K et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569
21. Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101-2103 (Pubitemid 30225166)
22. Woditschka S, Haag JD, Mau B, Lubet RA, Gould MN (2008) The chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. Breast Cancer Res 15(10):R18
23. Uefuji K, Ichikura T, Mochizuki H (2000) Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 6:135-138 (Pubitemid 30064985)
24. Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311 (Pubitemid 30151999)
25. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403 (Pubitemid 30212792)
26. Brueggemeier RW, Su B, Sugimoto Y, Díaz-Cruz ES, Davis DD (2007) Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol 106:16-23 (Pubitemid 47362646)
27. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112 (Pubitemid 37328797)
28. Thomas HV, Key TJ, Allen DS et al (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 75:1075-1079 (Pubitemid 27122629)
29. Reed MJ, Owen AM, Lai LC et al (1989) In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. Int J Cancer 44:233-237 (Pubitemid 19217207)
30. Zhou C, Zhou D, Esteban J et al (1996) Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 59:163-171 (Pubitemid 27036268)
31. Cuzick J (2008) Chemoprevention of breast cancer. Breast Cancer 15:10-16
32. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, PreSAP Trial Investigators (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895 (Pubitemid 44315981)
33. Harper-Wynne C, Ross G, Sacks N et al (2002) Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11:614-621 (Pubitemid 34760819)
34. Ellis PA, Smith IE, Detre S, Burton S, Salter J, A'hern R, Walsh G, Johnston SR, Dowsett M (1998) Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48:107-116 (Pubitemid 28156355)
35. Detre S, Salter J, Barnes DM, Riddler S, Hills M, Johnston SR, Gillett C, A'Hern R, Dowsett M (1999) Time-related effects of estrogen withdrawal on proliferation-And cell death related events in MCF7 xenografts. Int J Cancer 81:309-313 (Pubitemid 29144764)
36. Saccani Jotti G, Johnston SR, Salter J, Detre S, Dowsett M (1994) Comparison of new immunohistochemical assay for estrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzymeimmunoassay. J. Cin Pathol (Lond) 47:900-905
37. Davies G, Salter J, Hills M, Martin LA, Sacks N, DowsettM(2003) Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9:2651-2666
38. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177:275-283
39. Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532 (Pubitemid 34065880)
40. Harper-Wynne CL, Sacks NP, Shenton K et al (2002) Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20:1026-1035 (Pubitemid 34141847)
41. Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116 (Pubitemid 46224019)
42. Dowsett M, Ebbs SR, Dixon JM et al (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-A study from the IMPACT trialists. J Clin Oncol 223:2477-2492 (Pubitemid 47050838)
43. Dowsett M, Bundred NJ, Decensi A et al (2001) Effect of raloxifene on breast cancer cell Ki67 and apoptosis: A double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10:961-966 (Pubitemid 32844904)
44. Bundred NJ, Cramer A, Morris J et al (2010) Cyclooxygenase-2 inhibition does not improve the reduction of ductal carcinoma in situ proliferation with aromatase therapy: results of the ERISAC randomized placebo controlled trial. Clin Can Res 16:1605-1612
45. Tfayli A, Yang J, Kojouri K, Kesserwan C, Jafari M, Ozer H (2008) Neoadjuvant therapy with celecoxib in women with early stage breast cancer. Neoplasma 55:122-126
46. Hudson AG, Gierach GL, Modugno F et al (2008) Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:680-687 (Pubitemid 351469220)
47. Tiano HF, Loftin CD, Akunda J et al (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62:3395-3401 (Pubitemid 34651385)
48. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959 (Pubitemid 33010342)